Liver Cancer Diagnostics Market Analysis

Liver Cancer Diagnostics Market Analysis

To get key market trends

  Download Free Sample

Based on test type, the market is segmented as laboratory test, imaging test, biopsy, endoscopy, genomic test and others. The laboratory test segment dominated the liver cancer diagnostics market accounting over 32% revenue share in 2022. Laboratory tests for liver cancer diagnostics provide several benefits in the detection, diagnosis, and monitoring of hepatocellular carcinoma. Laboratory tests, such as blood tests and biomarker assays, can aid in the early detection of liver cancer. These tests can identify specific markers or molecules that are associated with liver cancer, even before symptoms manifest.

Early detection allows for timely intervention and treatment, which can improve patient outcomes and increase the chances of successful treatment. Laboratory tests play a crucial role in screening high-risk individuals for liver cancer and in surveillance for individuals with chronic liver diseases. For instance, individuals with chronic hepatitis B or C infections, alcoholic liver disease, or non-alcoholic fatty liver disease (NAFLD) may undergo regular liver function tests and biomarker tests to monitor liver health and detect any signs of liver cancer development.

Laboratory tests aid in staging liver cancer and determining the extent of disease spread. Biomarker tests, such as alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP), can provide information about tumor markers and help assess the prognosis of liver cancer patients. These tests assist healthcare providers in making informed decisions regarding treatment options and disease management. Laboratory tests in liver cancer diagnostics provide valuable information for early detection, screening, differential diagnosis, disease staging, treatment monitoring, and personalized medicine thereby augmenting the market growth.

Based on end-use, the liver cancer diagnostics market is segmented as hospitals, diagnostic laboratories, academic and research institutes and others. The hospitals segment captured a majority market share and is poised to grow at 7% CAGR through 2032. High adoption rates for technologically advanced biopsy, mammography, and other devices utilized in treatment of liver cancer will increase the number of diagnosis carried out in hospital settings. Availability of skilled professionals to operate advanced cancer diagnosis equipment as well as favorable reimbursement policies for liver cancer diagnosis procedures performed in hospital settings will surge the segment revenue.

Hospitals are adopting advanced diagnostic technologies such as biomarker assays, genetic profiling, and liquid biopsy techniques to improve the quality of patient care and outcomes. The management of liver cancer often requires a multidisciplinary approach involving various medical specialties, including hepatology, radiology, pathology, and oncology.

Hospitals are adopting liver cancer diagnostics to support collaboration and coordination among different departments, enabling accurate diagnosis, staging, and treatment planning. Furthermore, factors such as increase in the number of liver cancer diagnostic procedures and the availability of highly skilled healthcare professionals together with robust healthcare infrastructure and appropriate patient assistance that are complementing the growth of the hospitals segment positively. Thus, access to better treatment and diagnosis, combined with the increased prevalence of liver cancer, is expected to increase patient visits to hospitals, propelling segment revenue.

North America region held a dominant share in the global liver cancer diagnostics market and was valued at USD 4.4 billion in 2022. North America has a significant prevalence of risk factors associated with liver cancer, such as chronic hepatitis B and C infections, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). These risk factors contribute to the increasing incidence of liver cancer in the region, necessitating the demand for effective liver cancer diagnostics for early detection and intervention. Technological advancement in cancer diagnostic techniques, favorable R&D initiatives by industry players and government’s support towards development of advanced diagnostic platforms will favor industry growth.

Growing awareness among people regarding early disease diagnosis, availability of advanced healthcare infrastructure along with high healthcare expenditure will stimulate North America liver cancer diagnostics market growth. Aging population, increased awareness of preventive healthcare, and advancements in liver cancer diagnostics techniques is anticipated to boost the market growth. Thus, supporting initiatives aimed at improving healthcare outcomes, rising healthcare expenditure, and increasing disease prone population would drive the regional market revenue share positively.